Arformoterol
Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]
Clinical data | |
---|---|
Trade names | Brovana |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602023 |
License data |
|
Pregnancy category |
|
Routes of administration | Inhalation solution for nebuliser |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 52–65% |
Elimination half-life | 26 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H24N2O4 |
Molar mass | 344.411 g·mol−1 |
| |
|
It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
References
- "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.